Position of the Transparency Council – Nucala (mepolizumab)
At its meeting on 28 October 2024, the Transparency Council adopted position No. 114/2024 on the evaluation of the drug Nucala (mepolizumab) within the framework of the drug program “Treatment of patients with active eosinophilic granulomatosis with vasculitis (EGPA) (ICD-10: M30.1)”